Matthew Caufield

HC Wainwright & Co. | Healthcare

Matthew Caufield is an analyst from HC Wainwright & Co. specializing in the Healthcare sector. Ranked #183 out of 4580 analysts, they have issued 51 stock ratings with a success rate of 83.53% and an average return of 72.72%.

Matthew Caufield has a well-established track record, with 51 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 83.53% and an average return of 72.72%, underscoring their expertise and ability to identify winning opportunities for investors.

#183

Out of 4580

51

Total Ratings

+83.53%

Success Rate

+72.72%

Average Return

Recent Ratings Analysis

ALDX

Mar 18, 2026

Target

$2.00

Current

$1.24

Performance

—

Matthew Caufield rated ALDX as Neutral on Mar 18, 2026, setting a price target of 2. The Hold stance appears justified, as shares hovered around 1.24 with a % move.

ZBIO

Mar 17, 2026

Target

$44.00

Current

$23.48

Performance

0.00%

On Mar 17, 2026, ZBIO was given a Buy rating by Matthew Caufield, with a target price of 44. The stock traded sideways with a 0.00% move, keeping the bullish thesis unresolved.

IMUX

Mar 02, 2026

Target

$8.00

Current

$1.20

Performance

13.21%

IMUX received a Buy rating from Matthew Caufield on Mar 02, 2026, aiming for 8. Momentum has favored the Buy call, with shares climbing from 1.2 to 1.2, rewarding those who trusted the recommendation.

FBLG

Feb 26, 2026

Target

$5.00

Current

$0.28

Performance

-2.37%

On Feb 26, 2026, Matthew Caufield published a Buy outlook on FBLG, with a target of 5. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 0.2762.

ARDX

Feb 20, 2026

Target

$18.00

Current

$5.83

Performance

1.75%

Matthew Caufield on Feb 20, 2026 assigned ARDX a Buy rating, with a price target of 18. The recommendation remains pending validation as shares consolidate around 5.83.

KOD

Feb 10, 2026

Target

$38.00

Current

$23.85

Performance

2.27%

On Feb 10, 2026, Matthew Caufield reaffirmed KOD with a Buy rating, targeting 38. Market indecision has kept the 38 target in a holding pattern.

AKBA

Feb 06, 2026

Target

$6.00

Current

$1.49

Performance

7.19%

AKBA was rated Buy by Matthew Caufield on Feb 06, 2026, with a price objective of 6. A bullish response from the market helped close the gap of 4.51 to the target.

ADVM

Nov 17, 2025

Target

$5.00

Current

$4.36

Performance

2.11%

On Nov 17, 2025, Matthew Caufield initiated coverage on ADVM with a Neutral rating and target of 5. The stock’s lack of movement around 4.36 aligned with a cautious approach.

MLYS

Nov 12, 2025

Target

$56.00

Current

$25.02

Performance

-47.14%

Matthew Caufield issued a Buy recommendation for MLYS on Nov 12, 2025, price target set at 56. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

PHAT

Oct 31, 2025

Target

$26.00

Current

$10.85

Performance

-19.93%

On Oct 31, 2025, PHAT was evaluated by Matthew Caufield, who gave a Buy rating and target of 26. Investors saw limited payoff as shares fell short of the 26 target.

TARS

Oct 20, 2025

Target

$88.00

Current

$69.79

Performance

-1.97%

Matthew Caufield rated TARS as Buy on Oct 20, 2025, setting a price target of 88. Shares have remained stable near 69.79, leaving the 88 target still in play.

DMAC

Aug 15, 2025

Target

$12.00

Current

$7.16

Performance

18.74%

On Aug 15, 2025, DMAC was given a Buy rating by Matthew Caufield, with a target price of 12. The stock rallied 18.74% after the rating, narrowing the gap to the target of 12 and validating the bullish stance.

LYRA

Aug 14, 2025

Target

$16.00

Current

$0.49

Performance

-93.03%

LYRA received a Neutral rating from Matthew Caufield on Aug 14, 2025, aiming for 16. The Hold stance proved prudent, with the market softening by 93.03%.

LENZ

Aug 01, 2025

Target

$56.00

Current

$12.50

Performance

-58.28%

On Aug 01, 2025, Matthew Caufield published a Buy outlook on LENZ, with a target of 56. Market action contradicted the Buy thesis, as shares slipped to 12.5.

IRD

Jun 27, 2025

Target

$8.00

Current

$4.80

Performance

391.50%

Matthew Caufield on Jun 27, 2025 assigned IRD a Buy rating, with a price target of 8. The Buy call aligned well with market performance, producing a gain of 391.50%.

SRZN

Apr 02, 2025

Target

$32.00

Current

$25.60

Performance

115.85%

On Apr 02, 2025, Matthew Caufield reaffirmed SRZN with a Buy rating, targeting 32. The recommendation was supported by strong follow-through as the stock rose from 25.6 to 25.6.

HLVX

Mar 31, 2025

Target

$2.00

Current

$2.09

Performance

44.14%

HLVX was rated Neutral by Matthew Caufield on Mar 31, 2025, with a price objective of 2. Despite caution, upside momentum rewarded risk-takers with gains to 2.09.

OPT

Mar 25, 2025

Target

$2.00

Current

$3.41

Performance

0.00%

On Mar 25, 2025, Matthew Caufield initiated coverage on OPT with a Neutral rating and target of 2. The stock’s lack of movement around 3.41 aligned with a cautious approach.

UBX

Mar 25, 2025

Target

$4.00

Current

$0.20

Performance

-84.12%

Matthew Caufield issued a Buy recommendation for UBX on Mar 25, 2025, price target set at 4. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

OPTN

Mar 21, 2025

Target

$9.00

Current

$9.60

Performance

4.92%

On Mar 21, 2025, OPTN was evaluated by Matthew Caufield, who gave a Neutral rating and target of 9. Hold sentiment was validated by subdued trading with no breakout beyond 9.6.

EYEN

Mar 21, 2025

Target

$2.00

Current

$7.56

Performance

447.83%

Matthew Caufield rated EYEN as Neutral on Mar 21, 2025, setting a price target of 2. Despite the Hold call, shares climbed 447.83% to 7.56, revealing unexpected momentum.

FDMT

Mar 03, 2025

Target

$36.00

Current

$8.61

Performance

107.97%

On Mar 03, 2025, FDMT was given a Buy rating by Matthew Caufield, with a target price of 36. The stock rallied 107.97% after the rating, narrowing the gap to the target of 36 and validating the bullish stance.

OCUP

Aug 15, 2024

Target

$18.00

Current

$1.17

Performance

-5.65%

OCUP received a Buy rating from Matthew Caufield on Aug 15, 2024, aiming for 18. The rating hasn’t played out as hoped, with the stock trading 5.65% below expectations.

Frequency Asked Questions

Who is Matthew Caufield?

Matthew Caufield is an analyst from HC Wainwright & Co. specializing in the Healthcare sector.

What is Matthew Caufield's success rate?

Matthew Caufield currently has a success rate of +83.53%.

How many ratings has Matthew Caufield issued?

Matthew Caufield has issued 51 stock ratings so far.

What is the average return of Matthew Caufield's calls?

Their stock ratings have generated an average return of +72.72%.

What is Matthew Caufield's ranking?

Matthew Caufield is ranked #183 out of 4580 analysts.

What types of ratings does Matthew Caufield give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Matthew Caufield?

You can follow Matthew Caufield by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Matthew Caufield?

Their latest rating was a Hold on ALDX issued on 2026-03-18.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep